Medical Marijuana, Inc. Subsidiary HempMeds® Mexico Announces Results from Clinical Study Including Real Scientific Hemp Oil-X™ (RSHO-X™) on Patients with Tuberous Sclerosis Complex (TSC)

Cannabis, the Holy Grail and the Secrets of the Templars?
October 12, 2017
Colorado’s Pot Sales Exceed $1 Billion in First 8 Months of 2017
October 12, 2017

Medical Marijuana, Inc. Subsidiary HempMeds® Mexico Announces Results from Clinical Study Including Real Scientific Hemp Oil-X™ (RSHO-X™) on Patients with Tuberous Sclerosis Complex (TSC)

SAN DIEGO, Oct. 12, 2017 /PRNewswire/ — Medical Marijuana, Inc. (OTC: MJNA), the first publicly traded cannabis company in the U.S., today announced that a recent clinical study conducted by renowned Mexico neurologist, Dr. Carlos G. Aguirre-Velazquez, successfully utilized its flagship THC-free product Real Scientific Hemp Oil-X™ (RSHO-X™).

The study targeted the reduction in frequency, intensity and duration of convulsive crises in people with tuberous sclerosis complex (TSC) and saw promising results from cannabidiol (CBD) as a treatment for patients with TSC. Other factors observed in the study were quality of life, dependence on heavy prescription drugs and long-term sustainability of treatment with CBD.

The trial was comprised of patients with varying forms of epilepsy, with the majority having TSC, a genetic disorder characterized by the growth of noncancerous (benign tumors) in many parts of the body, including the brain, which can lead to convulsive crises. TSC affects 1 million people worldwide, 50,000 in the U.S. and 20,000 in Mexico.

Results from the trial showed that 60% of participants who used CBD products saw a clinically significant (80-100%) reduction in the frequency of their seizures. Additionally, quality of life metrics such as mood, appetite and cognition saw substantial increases among the patients using CBD. Finally, no serious side effects were reported, only mild ones such as drowsiness and increase in appetite, which eventually disappeared with the need to reduce the dose.

The study concludes that, “The experience of parents and patients with medicinal cannabis (CBD), as reported in our survey, suggests that CBD reduced the frequency, intensity, and duration of convulsive crises secondary to TSC.”

“Each time new study results are published showing the positive effects of CBD on a new indication is a victory for showcasing the therapeutic benefits of CBD and people around the world suffering from a multitude of debilitating conditions,” said Dr. Stuart Titus, CEO of Medical Marijuana, Inc. “We congratulate Dr. Aguirre for his work in unveiling, like he did in this study, that not only is CBD effective in relieving seizures, but also exhibiting that CBD can be used over long periods of time without harm, compared to antiepileptic or broad-spectrum steroids that can have dangerous side effects if used for several years, including vision and damage to major organs.”

HempMeds® Mexico’s zero-THC product RSHO-X™ was the first-ever cannabis product to receive approval from the federal government Continue Reading

Grow Gear Spreadshirt
*This page contains viral feeds. We aggregate all of this content. This site shares recent posts, images and links from viral sources. All material is copyright to their respectful sources and no copyright infringement is intended.

Leave a Reply

Are you over 18?

Please verify your age